Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.87 USD
Change Today +0.04 / 0.37%
Volume 1.3M
NKTR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (NKTR) Snapshot

Open
$10.65
Previous Close
$10.83
Day High
$11.00
Day Low
$10.64
52 Week High
12/2/14 - $17.53
52 Week Low
08/24/15 - $9.16
Market Cap
1.4B
Average Volume 10 Days
1.3M
EPS TTM
$0.03
Shares Outstanding
132.4M
EX-Date
--
P/E TM
362.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEKTAR THERAPEUTICS (NKTR)

nektar therapeutics (NKTR) Related Businessweek News

No Related Businessweek News Found

nektar therapeutics (NKTR) Details

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. The company offers MOVANTIK, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives. Its drug candidates in clinical development stage comprises BAX 855 that is in Phase III clinical trial for treating Hemophilia A; BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181 that is in Phase III clinical trial for chronic pain; NKTR-171, which is in Phase I clinical trial to treat neuropathic pain; and NKTR-214 that is in research and preclinical trial stage to treat oncology, as well as MOVANTIK, which is research and preclinical stage for treating chronic pain without constipation. The company’s drug candidates in clinical development stage also include etirinotecan pegol, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as has completed Phase II clinical trial stage for platinum-resistant/refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat gastrointestinal-related solid tumors, which has completed Phase I clinical trial. Nektar Therapeutics has collaboration with Baxter Healthcare; Bayer Healthcare LLC; and AstraZeneca AB. In addition, it has license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Halozyme Therapeutics, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche); and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

438 Employees
Last Reported Date: 02/26/15
Founded in 1990

nektar therapeutics (NKTR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $860.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $542.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $526.1K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $477.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $372.7K
Compensation as of Fiscal Year 2014.

nektar therapeutics (NKTR) Key Developments

Nektar Therapeutics Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Nektar Therapeutics announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company announced total revenue of $22,661,000 compared to $28,513,000 for the same period a year ago. The decrease in revenue was due to lower milestones from the company's collaboration partners, partially offset by higher product sales. Loss from operations was $43,469,000 compared to $22,916,000 for the same period a year ago. Loss before provision for income taxes was $52,493,000 compared to $32,442,000 for the same period a year ago. Net loss was $52,657,000 compared to $32,637,000 for the same period a year ago. Basic and diluted net loss per share was $0.40 compared to $0.26 for the same period a year ago. For the six months, the company announced total revenue of $131,462,000 compared to $48,284,000 for the same period a year ago. Loss from operations was $426,000 compared to $59,318,000 for the same period a year ago. Loss before provision for income taxes was $18,460,000 compared to $78,452,000 for the same period a year ago. Net loss was $18,837,000 compared to $78,838,000 for the same period a year ago. Basic and diluted net loss per share was $0.14 compared to $0.63 for the same period a year ago. Net cash provided in operating activities was $16,057,000 compared to net cash used in operating activities $71,375,000 for the same period a year ago. Purchases of property and equipment were $4,584,000 compared to $5,192,000 for the same period a year ago. The increase in revenue in the first half of 2015 as compared to the same period in 2014 is due to the recognition of $90.0 million of the $100.0 million payment from AstraZeneca following the first commercial sale of MOVANTIK in the U.S. The company's year-end cash guidance for 2015 remains unchanged, and the company still plan to end the year with approximately $200 million in cash and investments and does not include any royalties from MOVANTIK. This represents a net use of cash of approximately $63 million in 2015. Revenue for 2015 is still expected to be between $215 million and $225 million, including $19 million of noncash royalty revenue.

Nektar Therapeutics to Report Q2, 2015 Results on Aug 05, 2015

Nektar Therapeutics announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 05, 2015

Nektar Therapeutics, Q2 2015 Earnings Call, Aug 05, 2015

Nektar Therapeutics, Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $10.87 USD +0.04

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $28.38 USD -0.42
Emergent BioSolutions Inc $34.64 USD +0.36
Ironwood Pharmaceuticals Inc $11.27 USD +0.22
Sucampo Pharmaceuticals Inc $28.28 USD +0.36
Theravance Inc $13.82 USD 0.00
View Industry Companies
 

Industry Analysis

NKTR

Industry Average

Valuation NKTR Industry Range
Price/Earnings 100.0x
Price/Sales 5.0x
Price/Book 40.8x
Price/Cash Flow 235.6x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit www.nektar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.